SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.6352
+0.0028 (0.43%)
Jan 2, 2026, 2:30 PM EST - Market open
SCYNEXIS Revenue
SCYNEXIS had revenue of $334.00K in the quarter ending September 30, 2025, a decrease of -49.39%. This brings the company's revenue in the last twelve months to $2.93M, down -65.53% year-over-year. In the year 2024, SCYNEXIS had annual revenue of $3.75M, down -97.33%.
Revenue (ttm)
$2.93M
Revenue Growth
-65.53%
P/S Ratio
10.66
Revenue / Employee
$104,714
Employees
28
Market Cap
26.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.75M | -136.40M | -97.33% |
| Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
| Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
| Dec 31, 2021 | 13.16M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
| Dec 31, 2018 | 257.00K | - | - |
| Dec 31, 2017 | 257.00K | - | - |
| Dec 31, 2016 | 257.00K | - | - |
| Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
| Dec 31, 2014 | 1.26M | -8.31M | -86.87% |
| Dec 31, 2013 | 9.57M | 156.00K | 1.66% |
| Dec 31, 2012 | 9.41M | -3.42M | -26.67% |
| Dec 31, 2011 | 12.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SCYX News
- 11 days ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewsWire
- 2 months ago - SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - GlobeNewsWire
- 4 months ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire
- 5 months ago - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 10 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire